This company has been marked as potentially delisted and may not be actively trading.

Kezar Life Sciences (KZR) Competitors

KZR vs. VYGR, IKT, IPHA, MDWD, and WHWK

Should you buy Kezar Life Sciences stock or one of its competitors? MarketBeat compares Kezar Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kezar Life Sciences include Voyager Therapeutics (VYGR), Inhibikase Therapeutics (IKT), Innate Pharma (IPHA), MediWound (MDWD), and Whitehawk Therapeutics (WHWK). These companies are all part of the "pharmaceutical products" industry.

How does Kezar Life Sciences compare to Voyager Therapeutics?

Kezar Life Sciences (NASDAQ:KZR) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Kezar Life Sciences has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Kezar Life Sciences' return on equity of -55.42% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kezar Life Sciences	N/A	-55.42%	-47.87%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

In the previous week, Kezar Life Sciences and Kezar Life Sciences both had 1 articles in the media. Voyager Therapeutics' average media sentiment score of 0.76 beat Kezar Life Sciences' score of -0.25 indicating that Voyager Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kezar Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kezar Life Sciences has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kezar Life Sciences	N/A	N/A	-$56.03M	-$6.17	N/A
Voyager Therapeutics	$40.37M	5.69	-$119.72M	-$1.97	N/A

67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 10.4% of Kezar Life Sciences shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kezar Life Sciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Kezar Life Sciences presently has a consensus price target of $6.00, suggesting a potential downside of 17.70%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 334.21%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Kezar Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kezar Life Sciences	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Voyager Therapeutics beats Kezar Life Sciences on 10 of the 15 factors compared between the two stocks.

How does Kezar Life Sciences compare to Inhibikase Therapeutics?

Kezar Life Sciences (NASDAQ:KZR) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 10.4% of Kezar Life Sciences shares are owned by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Inhibikase Therapeutics' return on equity of -41.31% beat Kezar Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kezar Life Sciences	N/A	-55.42%	-47.87%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Kezar Life Sciences. MarketBeat recorded 2 mentions for Inhibikase Therapeutics and 1 mentions for Kezar Life Sciences. Inhibikase Therapeutics' average media sentiment score of 0.00 beat Kezar Life Sciences' score of -0.25 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kezar Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kezar Life Sciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Kezar Life Sciences presently has a consensus target price of $6.00, indicating a potential downside of 17.70%. Inhibikase Therapeutics has a consensus target price of $5.50, indicating a potential upside of 225.44%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Kezar Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kezar Life Sciences	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13

Inhibikase Therapeutics has higher revenue and earnings than Kezar Life Sciences. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kezar Life Sciences	N/A	N/A	-$56.03M	-$6.17	N/A
Inhibikase Therapeutics	$260K	858.20	-$48.26M	-$0.43	N/A

Summary

Inhibikase Therapeutics beats Kezar Life Sciences on 12 of the 15 factors compared between the two stocks.

How does Kezar Life Sciences compare to Innate Pharma?

Kezar Life Sciences (NASDAQ:KZR) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Kezar Life Sciences currently has a consensus target price of $6.00, indicating a potential downside of 17.70%. Innate Pharma has a consensus target price of $5.00, indicating a potential upside of 173.22%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than Kezar Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kezar Life Sciences	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Innate Pharma has higher revenue and earnings than Kezar Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kezar Life Sciences	N/A	N/A	-$56.03M	-$6.17	N/A
Innate Pharma	$10.19M	16.87	-$55.64M	N/A	N/A

In the previous week, Kezar Life Sciences had 1 more articles in the media than Innate Pharma. MarketBeat recorded 1 mentions for Kezar Life Sciences and 0 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.00 beat Kezar Life Sciences' score of -0.25 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Kezar Life Sciences	Neutral
Innate Pharma	Neutral

Innate Pharma's return on equity of 0.00% beat Kezar Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kezar Life Sciences	N/A	-55.42%	-47.87%
Innate Pharma	N/A	N/A	N/A

Kezar Life Sciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 10.4% of Kezar Life Sciences shares are held by company insiders. Comparatively, 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Innate Pharma beats Kezar Life Sciences on 10 of the 13 factors compared between the two stocks.

How does Kezar Life Sciences compare to MediWound?

MediWound (NASDAQ:MDWD) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

46.8% of MediWound shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MediWound presently has a consensus price target of $35.00, indicating a potential upside of 111.10%. Kezar Life Sciences has a consensus price target of $6.00, indicating a potential downside of 17.70%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Kezar Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kezar Life Sciences	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

MediWound has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Kezar Life Sciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

MediWound has higher revenue and earnings than Kezar Life Sciences. MediWound is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	12.56	-$23.88M	-$2.10	N/A
Kezar Life Sciences	N/A	N/A	-$56.03M	-$6.17	N/A

In the previous week, MediWound and MediWound both had 1 articles in the media. MediWound's average media sentiment score of 0.00 beat Kezar Life Sciences' score of -0.25 indicating that MediWound is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kezar Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kezar Life Sciences has a net margin of 0.00% compared to MediWound's net margin of -140.80%. Kezar Life Sciences' return on equity of -55.42% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-140.80%	-65.79%	-30.16%
Kezar Life Sciences	N/A	-55.42%	-47.87%

Summary

MediWound beats Kezar Life Sciences on 8 of the 14 factors compared between the two stocks.

How does Kezar Life Sciences compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Whitehawk Therapeutics currently has a consensus target price of $7.33, indicating a potential upside of 63.33%. Kezar Life Sciences has a consensus target price of $6.00, indicating a potential downside of 17.70%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Kezar Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kezar Life Sciences	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Whitehawk Therapeutics had 2 more articles in the media than Kezar Life Sciences. MarketBeat recorded 3 mentions for Whitehawk Therapeutics and 1 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of -0.25 beat Whitehawk Therapeutics' score of -0.25 indicating that Kezar Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kezar Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kezar Life Sciences' return on equity of -55.42% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Kezar Life Sciences	N/A	-55.42%	-47.87%

Whitehawk Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Kezar Life Sciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Whitehawk Therapeutics has higher revenue and earnings than Kezar Life Sciences. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	31.10	-$20.60M	-$1.68	N/A
Kezar Life Sciences	N/A	N/A	-$56.03M	-$6.17	N/A

Summary

Whitehawk Therapeutics beats Kezar Life Sciences on 9 of the 14 factors compared between the two stocks.

Get Kezar Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZR vs. The Competition

Export

Metric	Kezar Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.86M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.18	18.74	21.00	25.66
Price / Sales	N/A	323.98	562.18	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	0.76	7.09	10.41	7.14
Net Income	-$56.03M	$24.45M	$3.57B	$335.98M

Kezar Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZR Kezar Life Sciences	0.7867 of 5 stars	$7.29 flat	$6.00 -17.7%	+85.5%	$53.86M	N/A	N/A	60	High Trading Volume
VYGR Voyager Therapeutics	2.9248 of 5 stars	$3.48 -1.4%	$16.50 +374.1%	+30.1%	$213.29M	$40.37M	N/A	100
IKT Inhibikase Therapeutics	1.5154 of 5 stars	$1.57 -2.5%	$5.50 +250.3%	N/A	$212.57M	$260K	N/A	6	News Coverage Gap Up
IPHA Innate Pharma	2.5818 of 5 stars	$2.03 -9.8%	$5.00 +146.3%	-15.1%	$211.32M	$10.19M	N/A	220	Gap Down
MDWD MediWound	1.6466 of 5 stars	$16.68 +1.7%	$35.00 +109.8%	-18.6%	$210.78M	$16.96M	N/A	80	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZR) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kezar Life Sciences (KZR) Competitors

KZR vs. VYGR, IKT, IPHA, MDWD, and WHWK

How does Kezar Life Sciences compare to Voyager Therapeutics?

Summary

How does Kezar Life Sciences compare to Inhibikase Therapeutics?

Summary

How does Kezar Life Sciences compare to Innate Pharma?

Summary

How does Kezar Life Sciences compare to MediWound?

Summary

How does Kezar Life Sciences compare to Whitehawk Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR vs. The Competition

Kezar Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kezar Life Sciences (KZR) Competitors

KZR vs. VYGR, IKT, IPHA, MDWD, and WHWK

How does Kezar Life Sciences compare to Voyager Therapeutics?

Is KZR or VYGR more profitable?

Does the media refer more to KZR or VYGR?

Which has stronger valuation & earnings, KZR or VYGR?

Do institutionals & insiders hold more shares of KZR or VYGR?

Which has more volatility and risk, KZR or VYGR?

Do analysts prefer KZR or VYGR?

Summary

How does Kezar Life Sciences compare to Inhibikase Therapeutics?

Do institutionals and insiders believe in KZR or IKT?

Is KZR or IKT more profitable?

Does the media refer more to KZR or IKT?

Which has more volatility & risk, KZR or IKT?

Do analysts prefer KZR or IKT?

Which has higher earnings & valuation, KZR or IKT?

Summary

How does Kezar Life Sciences compare to Innate Pharma?

Do analysts rate KZR or IPHA?

Which has stronger valuation and earnings, KZR or IPHA?

Does the media prefer KZR or IPHA?

Is KZR or IPHA more profitable?

Which has more risk & volatility, KZR or IPHA?

Do insiders & institutionals believe in KZR or IPHA?

Summary

How does Kezar Life Sciences compare to MediWound?

Do insiders and institutionals believe in MDWD or KZR?

Do analysts rate MDWD or KZR?

Which has more volatility & risk, MDWD or KZR?

Which has better earnings & valuation, MDWD or KZR?

Does the media prefer MDWD or KZR?

Is MDWD or KZR more profitable?

Summary

How does Kezar Life Sciences compare to Whitehawk Therapeutics?

Do analysts rate WHWK or KZR?

Do insiders & institutionals have more ownership in WHWK or KZR?

Does the media prefer WHWK or KZR?

Is WHWK or KZR more profitable?

Which has more volatility and risk, WHWK or KZR?

Which has higher valuation & earnings, WHWK or KZR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR vs. The Competition

Kezar Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools